BioSpace News Archive

Nutriband Inc. announced an expanded product development pipeline for its proprietary AVERSA™ abuse deterrent transdermal technology.

Worldwide Clinical Trials, Inc. and Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced a collaboration to enable enhanced decentralized clinical trial delivery in which patient visits for the provision of healthcare.

Evaxion Biotech A/S (NASDAQ: EVAX), announced today it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase 2b trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

Erasca, Inc. today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research.

PDS Biotechnology Corporation announced that its management will present at the B. Riley Securities Virtual Oncology Conference on January 28, 2022.

VBL Therapeutics today announced the appointment of Matthew Trudeau to the newly created position of Chief Commercial Officer (CCO).

SciSparc Ltd. (NASDAQ: SPRC), today announced that it has entered into an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel-Aviv Sourasky Medical School, in Tel-Aviv, Israel, to further its Phase IIb clinical study for SCI-110.

BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease.

Rallybio Corporation today announced that Ami Bavishi has joined as the company’s Head of Investor Relations and Corporate Communications.

Triumvira Immunologics today announced that the company formed its inaugural Scientific Advisory Board (SAB), comprising four leading scientists and physicians.